Wuhan Keqian Biology Co.,Ltd
SSE:688526.SS
17 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 941.924 | 1,064.075 | 1,001.268 | 1,103.021 | 843.228 | 507.511 | 735.3 | 632.835 | 390.398 |
| Cost of Revenue
| 341.394 | 296.947 | 264.225 | 222.757 | 145.191 | 106.137 | 114.525 | 98.281 | 81.969 |
| Gross Profit
| 600.53 | 767.128 | 737.042 | 880.264 | 698.037 | 401.374 | 620.775 | 534.554 | 308.429 |
| Gross Profit Ratio
| 0.638 | 0.721 | 0.736 | 0.798 | 0.828 | 0.791 | 0.844 | 0.845 | 0.79 |
| Reseach & Development Expenses
| 0 | 88.505 | 102.749 | 80.003 | 59.078 | 47.365 | 47.645 | 53.056 | 21.551 |
| General & Administrative Expenses
| 0 | 17.831 | 14.954 | 27.697 | 11.644 | 9.5 | 10.787 | 8.574 | 17.496 |
| Selling & Marketing Expenses
| 0 | 154.836 | 159.885 | 133.925 | 112.841 | 84.327 | 112.705 | 86.136 | 58.279 |
| SG&A
| 71 | 172.667 | 174.839 | 161.622 | 124.485 | 93.827 | 123.492 | 94.71 | 75.775 |
| Other Expenses
| 4.561 | 46.824 | 33.396 | 38.891 | 16.453 | 7.1 | -0.102 | -0.208 | 5.854 |
| Operating Expenses
| 161.682 | 283.518 | 310.984 | 280.516 | 200.017 | 148.292 | 192.279 | 167.227 | 99.372 |
| Operating Income
| 438.848 | 459.132 | 466.714 | 661.002 | 524.31 | 279.054 | 451.901 | 376.546 | 209.94 |
| Operating Income Ratio
| 0.466 | 0.431 | 0.466 | 0.599 | 0.622 | 0.55 | 0.615 | 0.595 | 0.538 |
| Total Other Income Expenses Net
| -0.715 | -1.551 | -0.107 | -0.953 | -4.649 | -0.754 | -0.102 | -0.208 | 5.854 |
| Income Before Tax
| 438.133 | 457.581 | 466.608 | 660.049 | 519.661 | 278.301 | 451.8 | 376.338 | 215.794 |
| Income Before Tax Ratio
| 0.465 | 0.43 | 0.466 | 0.598 | 0.616 | 0.548 | 0.614 | 0.595 | 0.553 |
| Income Tax Expense
| 56.643 | 62 | 57.461 | 89.413 | 71.858 | 35.658 | 62.886 | 56.026 | 29.627 |
| Net Income
| 382.35 | 395.935 | 409.518 | 570.741 | 447.803 | 242.642 | 388.969 | 320.318 | 186.158 |
| Net Income Ratio
| 0.406 | 0.372 | 0.409 | 0.517 | 0.531 | 0.478 | 0.529 | 0.506 | 0.477 |
| EPS
| 0.8 | 0.85 | 0.88 | 1.23 | 0.96 | 0.52 | 1.08 | 0.89 | 0.52 |
| EPS Diluted
| 0.8 | 0.85 | 0.88 | 1.23 | 0.96 | 0.52 | 1.08 | 0.89 | 0.52 |
| EBITDA
| 552.403 | 580.373 | 569.897 | 638.349 | 557.462 | 290.23 | 465.875 | 382.262 | 214.062 |
| EBITDA Ratio
| 0.586 | 0.545 | 0.569 | 0.579 | 0.661 | 0.572 | 0.634 | 0.604 | 0.548 |